Early Stage Companies to Present at CHI's Emerging Diagnostic Partnering & Investment Forum

July 9, 2012 - PRLog -- The pace of innovation, both technically and in terms of commercialization strategies, continues to accelerate within the field of molecular diagnostics, making the right strategic partnerships critical to the development of promising new technologies and applications.  

CHI’s Emerging Diagnostic Partnering & Investment Forum will bring together exciting early stage companies with decision makers representing pharma, larger biotechs, and VCs, providing a unique opportunity to learn about emerging technologies and engage in networking, partnering and investment exploration discussions.

The forum will highlight novel technologies and platforms in point-of-care, clinical sequencing and gene detection, with applications for infectious disease and cancer that exemplify where the diagnostics field is headed.

Presenting companies include:

Aviana Molecular Technologies
InstantLabs
MZ Diagnostics
Xagenic
IVDiagnostics
Epic Sciences
AnalizaDx
GeneCentric Diagnostics
Genomic Expression
SpeeDx
AquaBioChip
Adarza BioSystems
Biocartis
iCubate, Inc.
MBio Diagnostics
Daktari Diagnostics, Inc.
Surnetics
EyeNetra.com

View the the full agenda and register at http://www.NextGenerationDx.com/Dx-Partnering

To inquire about sponsoring and/or exhibiting, contact Joseph Vacca, 781-972-5431, jvacca@healthtech.com

About Cambridge Healthtech Institute (www.chicorporate.com)

CHI is the preeminent life science network for leading researchers and business experts from top pharmaceutical, biotech and academic organizations. CHI’s portfolio of products includes Cambridge Healthtech Institute Conferences, Insight Pharma Reports, Cambridge Marketing Consultants, Barnett Educational Services, Cambridge Meeting Planners and CHI’s Media Group, which includes news websites and e-newsletters including Bio-IT World and eCliniqua. Founded in 1992, CHI strives to develop quality information sources that provide valuable new insights and competing points of view while offering balanced coverage of the latest developments.

Contact:

James Prudhomme
Cambridge Healthtech Institute
781-972-5400
jprudhomme@healthtech.com